Jan. 15 at 9:14 PM
$APLT Remember do your DD, This might be out-dated though, as I just started looking into it now....
The merger/transaction involves a tender offer for
$0.088 per share in cash plus a contingent value right (CVR) for potential additional payments based on certain milestones. The merger is expected to close in the first quarter of 2026, subject to customary conditions.
The CVR is reported to be up to
$0.40 per share total based on approvals and sales.
This was from early December 2025...
Personally not a fan of the CVR stuff from previous experience.
Milestone 1 — Galactosemia FDA Approval
$0.10 per CVR
Milestone 2 — CMT-SORD FDA Approval (( Believe this is currently happening))
Another
$0.10 per CVR
Milestone 3 — Net Sales Achievement
$0.20 per CVR is payable if worldwide net sales of a covered product containing govorestat reach or exceed
$200 million in any four-quarter period before the 10th anniversary of closing
